Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: Implications for immunotherapy

Melanoma Research

Volumn 16, Issue 2, 2006, Pages 137-145

  Trefzer, Uwe ^a   Hofmann, Maja ^a   Reinke, Susanne ^a   Guo, Ya Jun ^b   Audring, Heike ^a   Spagnoli, Giulio ^c   Sterry, Wolfram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Eastern Institute of Hepatobiliary Surgery   (China)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Concordant loss; Immunotherapy; Melanoma; Tumour antigens; Tumour escape

Indexed keywords

CANCER TESTIS ANTIGEN; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 57 B; MONOCLONAL ANTIBODY 77 B; MONOCLONAL ANTIBODY SM 5 1; MONOPHENOL MONOOXYGENASE; PROTEIN S 100; TUMOR ANTIGEN; UNCLASSIFIED DRUG; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; MEMBRANE PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MELANOGENESIS; MELANOMA; PREDICTION; PRIORITY JOURNAL; SKIN METASTASIS; STAINING; TISSUE FIXATION; TISSUE SECTION; CELL DIFFERENTIATION; IMMUNOTHERAPY; METABOLISM; METASTASIS; PATHOLOGY;

ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745892910     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000200489.55099.20     Document Type: Article

References (41)

1. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998; 161:6970-6976.
2. de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997; 57:3223-3229.
3. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART-1 and Melan-A (the NIH experience). Am J Surg Pathol 1999; 23:607-610.
4. Zuber M, Spagnoli GC, Kocher T, Luscher U, Schaefer C, Noppen C, et al. Heterogeneity of melanoma antigen-1 (MAGE-1) gene and protein expression in malignant melanoma. Eur Surg Res 1997; 29:403-410.
5. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995; 63:375-380.
6. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154:3961-3968.
7. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997; 3:37-44.
8. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000; 165:3492-3496.
9. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-182.
10. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25:340-347.
11. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 1984; 2:161-166.
12. Trefzer U, Rietz N, Chen Y, Audring H, Herberth G, Siegel P, et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res 2000; 292:583-589.
13. Gudat F, Zuber M, Durmuller U, Kocher T, Schaefer C, Noppen C, et al. The tumour-associated antigen MAGE-1 is detectable in formalin-fixed paraffin sections of malignant melanoma. Virchows Arch 1996; 429:77-81.
14. Hofbauer GF, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle FO, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151:1549-1553.
15. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94:1156-1164.
16. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000; 86:835-841.
17. Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother 2000; 48:661-672.
18. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998; 111:233-238.
19. Watters D, Garrone B, Coomer J, Johnson WE, Brown G, Parsons P. Stimulation of melanogenesis in a human melanoma cell line by bistratene A. Biochem Pharmacol 1998; 55:1691-1699.
20. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, et al. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998; 77:200-204.
21. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:42-47.
22. Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U. Natural T cell immunity against cancer. Clin Cancer Res 2003; 9:4296-4303.
23. Albino AP, Fountain JW. Molecular genetics of human malignant melanoma. Cancer Treat Res 1993; 65:201-255.
24. Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol 2004; 165:1853-1863.
25. Urosevic M, Dummer R. HLA-G in skin cancer: a wolf in sheep's clothing? Hum Immunol 2003; 64:1073-1080.
26. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A. Tolerization of dendritic cells by HLA-G. Eur J Immunol 2005; 35:1133-1142.
27. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest 1998; 101:2720-2729.
28. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 1993; 91:684-692.
29. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87:284-292.
30. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75:517-524.
31. Brouwenstijn N, Slager EH, Bakker AB, Schreurs MW, Van der Spek CW, Adema GJ, et al. Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 1997; 76:1562-1566.
32. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92:8125-8129.
33. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, et al. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-5919.
34. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996; 19:192-205.
35. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
36. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94:805-818.
37. Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, et al. Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunol Immunother 2005; 54:208-218.
38. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor, in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21:4016-4026.
39. Harris HW, Gill TJ. Expression of class I transplantation antigens. Transplantation 1986; 42:109-117.
40. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272:1947-1950.
41. Le Poole IC, Riker AI, Quevedo ME, Stennet LS, Wang E, Marincoly FM, et al. Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002; 160:521-528.